GlassScriptPhysician profile
Boutros Zeidan
NPI 1043204134
$4,994.03
in general payments reported to CMS, 2019-2025
22 companies · $692 in 2025
The $692 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $904 · 2020: $495 · 2021: $1,169 · 2022: $470 · 2023: $612 · 2024: $652 · 2025: $692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,855 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,854.82 |
| Education | $100.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,699.86 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $824.81 | 2019-2023 | Nucala, Trelegy Ellipta, Arexvy |
| Ethicon INC. | $766.38 | 2021-2024 | Monarch Platform |
| Regeneron Healthcare Solutions, INC. | $436.08 | 2019-2024 | Dupixent |
| Grifols USA, LLC | $239.12 | 2019-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $189.76 | 2019-2025 | |
| Verona Pharma, INC. | $150.17 | 2025 | Ohtuvayre |
| Actelion Pharmaceuticals US, INC. | $143.27 | 2022-2024 | Opsumit, Uptravi |
| Axsome Therapeutics, INC. | $141.76 | 2023-2025 | Sunosi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.88 | 2019 | |
| Foundation Medicine, INC. | $49.09 | 2019 | |
| Genentech USA, INC. | $47.75 | 2019 | |
| Harmony Biosciences LLC | $41.49 | 2021-2023 | Wakix |
| Jazz Pharmaceuticals INC. | $33.67 | 2019 | |
| Preventice Services, LLC | $33.06 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $25.06 | 2019 | |
| Janssen Pharmaceuticals, INC | $21.72 | 2024 | Xarelto |
| Amgen INC. | $20.68 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.84 | 2019 | |
| Insmed, INC. | $14.68 | 2025 | Arikayce |
| Alnylam Pharmaceuticals INC. | $13.58 | 2020 | |
| Allergan, INC. | $12.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Boutros Zeidan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.